Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab in STEMI Patients Undergoing Primary PCI
NCT04303377Phase 2Withdrawn
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Nov 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in ST elevation myocardial infarction (STEMI), sponsored by IRCCS San Matteo Foundation. Planned start Nov 2019; status: withdrawn.
02
Drugs
evolocumab
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT04303377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303377.